Raloxifene Reduces the vertebral risk of the fracture in postmenopausal women(woman) with osteoporosis and stated osteoporosis, but efficiency in woman with osteopenia does not concern with. The Purpose of this analysis must value the effect raloxifene hydrochloride in risk vertebral fracture in postmenopausal woman with osteopenia and to compare this effect with that in woman with osteoporosis as defined bone mineral density (BMD) T-score on hip. We studied 3204 postmenopausal womans with osteopenia or osteoporosis without vertebral fracture in baseline in Multiple Outcome of trail of the Estimation Raloxifene. In contrast with плацебом, 60 mg./deni raloxifene reduced risk new vertebral fracture in 3 independent baseline to form the hip BMD. The Relative risk for new vertebral fracture for group raloxifene in contrast with placebo was 0.53 (95% CI, 0.32-0.88) for with osteopenia and 0.31 (0.06-0.71) for with osteoporosis. In raloxifene- turned woman, factor of the vertebral fracture was similar in woman with osteoporosis (2%) on that in woman with osteopenia (1.9%). For clinical evident vertebral fracture, the relative risk of the fracture in group osteopenia for raloxifene was 0.25 (0.04-0.63) in contrast with плацебом. Was Not no new clinical vertebral fracture in woman with osteoporosis getting raloxifene since four occurred in group плацеба. We solve that processing with 60 mg./dnem raloxifene vastly reduction risk new vertebral fracture and new clinical vertebral fracture in postmenopausal woman without base vertebral fracture, which have osteopenia or osteoporosis.

Tags: Evista, Raloxifene

This entry was posted on Пятница, Декабрь 25th, 2009 at 15:11 and is filed under Woman Health, Woman health articles. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.